LILIAN IKE: Open Payments
NPI 1851806574 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,573 in 72 payments from 9 companies in 2025. Trend: 2023 $839 · 2024 $942 · 2025 $1,573
Food & beverage: $1,573
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $371 |
| Supernus Pharmaceuticals, Inc. | 41 | $344 |
| Janssen Pharmaceuticals, Inc | 7 | $236 |
| Teva Pharmaceuticals USA, Inc. | 9 | $229 |
| E.R. Squibb & Sons, L.L.C. | 5 | $149 |
| Alkermes, Inc. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Lundbeck LLC | 1 | $27 |
| Almatica Pharma LLC | 1 | $26 |
Products named: Qelbree, UZEDY, INVEGA, COBENFY, ARISTADA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, REXULTI.
Industry payments across TX — which companies pay providers there.
